First discovered by neurologist Jean-Martin Charcot in 1869, Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a fatal age-related progressive neurodegenerative disease [8, 9]. It first arises within the central nervous system (CNS) and then spreads ceaselessly. ALS is characterised by the selective denervation and death of lower (LMN) and upper motor neurons (UMN). It is the most common motor neuron disease with an incidence of 1.5 to 2 per 100 000 individuals per year with an estimated prevalence of 12 000 people within the total US population [10, 11]. On average, newly diagnosed patients die within 3 to 5 years from onset after succumbing to respiratory failure due to muscle atrophy and weakness [12,13]. Approximately
